UK-based MedTech company, 4D Medicine, has raised £3.4 million in Series A investment to advance its development of biomaterials for 3D-printed implants and surgical devices. The company has created a resorbable biomaterial named 4Degra, which has been used to produce implants such as orthopaedic devices and soft tissue scaffolds to support patient rehabilitation following surgery or injury. The biomaterial gradually disintegrates and is absorbed by natural metabolic processes as natural tissue regenerates. The funding will be used to complete pre-clinical testing of its first product range and seek clearance from the FDA for entry into the US market. The latest funding brings the company’s total raised capital to £5m, with plans to raise a Series B investment in early 2022. The investment round was led by Oshen Holdings, with support from DSW Ventures, SFC Capital, Boundary Capital, and private investors, including scientists and surgeons.
The CEO of 4D Medicine, Philip Smith, expressed gratitude to the investors for their trust and support. He stated that the company’s ability to raise investment despite difficult market conditions attested to investors’ confidence in the company’s commercial potential and world-class team. Additionally, Oshen Holdings partner, Didier Cowling, expressed optimism about the company’s impact in the bioresorbable medical device market, adding that they are enabling 4D to develop bioresorbable medical devices with unique properties. Doug Quinn, Partner at DSW Ventures, stated that the company’s biomaterial platform is opening up new possibilities for implants and devices. He added that 4D’s funding would enable the company to target opportunities in the £5 billion market for resorbable medical devices.
In conclusion, 4D Medicine’s latest funding round marks a significant milestone in the development of its innovative biomaterials for use in 3D-printed implants and surgical devices. With the support of its investors, the company is poised to make a substantial impact in the bioresorbable medical device space and contribute to improving patient care.
